tiprankstipranks
Trending News
More News >

Argenica Therapeutics Expands ASX Quotation with New Securities

Story Highlights
  • Argenica Therapeutics focuses on developing novel therapeutics in the biotech industry.
  • The company quoted 11,522 new securities on the ASX to enhance its capital structure.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Argenica Therapeutics Expands ASX Quotation with New Securities

Don’t Miss TipRanks’ Half-Year Sale

Argenica Therapeutics Ltd ( (AU:AGN) ) has issued an announcement.

Argenica Therapeutics Ltd has announced the quotation of 11,522 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 7, 2025. This move is part of the company’s strategy to enhance its capital structure by exercising options or converting other securities, potentially impacting its market positioning and providing opportunities for stakeholders.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Ltd operates in the biotechnology industry, focusing on the development of novel therapeutics. The company’s primary products or services are centered around innovative treatments, with a market focus on addressing unmet medical needs.

Average Trading Volume: 94,515

Technical Sentiment Signal: Buy

See more data about AGN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1